Clinical trials
Adverse Event clinical trials
Below are recruiting adverse event clinical trials, each written for real people, not researchers. We’re tracking 191 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05786274Recruiting
Predicting stroke risk after heart surgery using heart signals and MRI
This study looks at ways to predict harmful brain and blood-vessel side effects after heart surgery. It may help doctors identify higher-risk patients sooner so they can monitor them more closely.
San Donato Milanese, MilanAges 18 years+ - NCT06696755RecruitingPhase 2
Study of icalcaprant for bipolar depression
This study tests an oral medication called icalcaprant for adults with bipolar I or II who are currently in a depressive episode. The goal is to see if it reduces symptoms and whether it's safe when taken alongside your usual mood stabilizer.
Huntsville, AlabamaAges 18–65 - NCT06953960RecruitingPhase 1/Phase 2
Surzetoclax for multiple myeloma with or without other drugs
This trial tests a new oral drug called surzetoclax, alone or with other myeloma treatments, for people with a specific type of multiple myeloma. It aims to see if the drug is safe and helps control the disease.
Los Angeles, CaliforniaAges 18 years+ - NCT06810505RecruitingPhase 3
Oral atogepant for preventing migraines in teens
This trial tests an oral medication called atogepant to see if it can prevent migraines in teens aged 12–17. It aims to reduce how often migraines happen and track any side effects.
Huntsville, AlabamaAges 12–17 - NCT06820970Recruiting
Combined therapy for heart artery blockages that weren't fully opened
This trial tests if combining a new heart procedure with a special type of therapy called mindfulness therapy can help prevent heart problems in people with coronary artery disease that could not be fully fixed with stents or surgery.
Zhengzhou, HenanAges 18 years+ - NCT06846320RecruitingPhase 2
Study of ABBV-932 for generalized anxiety disorder
This trial tests an oral medicine called ABBV-932 when added to current antidepressant therapy for people with generalized anxiety disorder (GAD) who still have symptoms. It aims to see if the combination can improve anxiety and reduce side effects.
Huntsville, AlabamaAges 18–65 - NCT06851702Recruiting
Tracking hormone side effects from immunotherapy in blood cancer
This study looks at people with certain types of blood cancer (lymphoma or leukemia) who are getting immunotherapy drugs called checkpoint inhibitors. Researchers want to learn how these drugs affect the body's hormone system, so doctors can better manage these side effects.
Bologna, BolognaAges 18 years+ - NCT06858813RecruitingPhase 1
ABBV-324 for advanced liver or lung cancer
This study tests an experimental IV drug (ABBV-324) for adults with advanced liver cancer (HCC) or advanced squamous lung cancer (LUSC). It aims to see if the drug is safe and whether it can help control the disease.
Duarte, CaliforniaAges 18 years+ - NCT06896916RecruitingPhase 1
Study of etentamig and a CELMoD drug for relapsed multiple myeloma
This trial tests a new combination of two drugs—etentamig given through a vein and a CELMoD pill—for people whose multiple myeloma has come back or stopped responding to treatment. The goal is to see if this combination is safe and helps control the disease.
Beverly Hills, CaliforniaAges 18 years+ - NCT07004452Recruiting
Predicting heart risks in younger adults with early heart disease
This study uses a multi-modal approach to predict adverse events in adults aged 18-45 with premature coronary heart disease. It aims to improve risk prediction and management for younger patients.
BeijingAges 18–45 - NCT07005102RecruitingPhase 2/Phase 3
Telisotuzumab adizutecan and osimertinib for EGFR-positive lung cancer
This trial tests a new drug combination (telisotuzumab adizutecan plus osimertinib) as a first treatment for adults with a specific type of advanced lung cancer that has an EGFR mutation. The goal is to see if the combination is safe and works better than standard care.
Chandler, ArizonaAges 18 years+ - NCT07017283Recruiting
Comparing two sedation methods for older adults having ERCP
This study compares two ways of keeping you comfortable and safe during an ERCP procedure: deeper sedation with a breathing tube versus deep sedation without a breathing tube. It aims to find which method causes fewer side effects in older adults.
Hangzhou, ZhijiangAges 60 years+ - NCT07024784RecruitingPhase 2
Study of IMGN151 for gynecologic cancers
This study tests a new drug (IMGN151) given intravenously, alone or with other therapies, for people with certain gynecologic cancers, specifically high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see how well it works and what side effects might occur.
Teaneck, New JerseyAges 18 years+ - NCT07044687RecruitingPhase 4
Venetoclax with azacitidine for newly diagnosed AML
This trial tests a combination of oral venetoclax and injected azacitidine for adults who are newly diagnosed with acute myeloid leukemia (AML) and cannot have standard strong chemotherapy. The goal is to see how well this treatment works and what side effects it may cause.
Gurgaon, HaryanaAges 18 years+ - NCT07058454Recruiting
Heart safety study for targeted cancer therapies
This study looks at how targeted cancer treatments affect the heart. If you are an adult with any type of cancer and are getting or will get chemotherapy (including targeted drugs), joining this study helps doctors understand heart risks better.
Guangzhou, GuangdongAges 18 years+ - NCT07095452RecruitingPhase 2/Phase 3
Newly diagnosed myeloma: comparing drug combinations for non-transplant patients
This trial tests a new combination of two drugs (etentamig and daratumumab) against the current standard of daratumumab plus lenalidomide and dexamethasone in people recently diagnosed with multiple myeloma who cannot have a stem cell transplant. The goal is to see which combination better controls the disease while keeping side effects manageable.
Scottsdale, ArizonaAges 18 years+ - NCT07139860Recruiting
AI system for early warning after a heart attack
This study tests an artificial intelligence system that watches for early signs of complications after a heart attack. If you join, the system may help doctors catch problems sooner.
BeijingAges 18 years+ - NCT07145918RecruitingPhase 2
Study of an oral schizophrenia drug for adults
This trial tests an experimental oral drug (emraclidine) to see if it helps symptoms of schizophrenia and how it moves through the body. It looks at two groups of participants: those with stable symptoms and those having an acute flare-up.
Little Rock, ArkansasAges 18–65 - NCT07167251Recruiting
Low-dose steroids for immunotherapy-related liver inflammation
This trial tests whether using low-dose steroids can safely manage liver inflammation caused by immunotherapy. It may help patients who have moderate liver problems from their cancer treatment but haven't yet started high-dose steroids.
Basel, Canton of Basel-CityAges 18 years+ - NCT07219030RecruitingPhase 1
Study of emraclidine in healthy older adults
This study tests how the drug emraclidine moves through the body in healthy older adults. It helps researchers understand how the drug is processed and whether it is safe.
Cypress, CaliforniaAges 65–85 - NCT07222709RecruitingPhase 1
Healthy volunteer study of oral ABBV-1042
This trial tests the safety of a new oral drug, ABBV-1042, in healthy adults. It helps researchers understand how the drug moves through the body and what side effects may occur.
Grayslake, IllinoisAges 18–55 - NCT07230288RecruitingPhase 2
Study of ABBV-142 for Idiopathic Pulmonary Fibrosis
This trial is testing a new antibody drug, ABBV-142, to see if it can reduce disease activity in adults with idiopathic pulmonary fibrosis (IPF). It may help if your IPF was diagnosed within the last 7 years and you meet certain health criteria.
Dothan, AlabamaAges 40 years+ - NCT07241039RecruitingPhase 1
Study of an oral drug for advanced squamous cell cancers
This study tests an oral drug called ABBV-711, alone or with another drug, for adults with advanced squamous cell cancers of the head, neck, or lung that have stopped responding to standard treatments. It aims to see how safe and effective the drug is.
Duarte, CaliforniaAges 18 years+ - NCT07249060Recruiting
Interferon levels in cancer and autoimmune disease patients
This study looks at a protein called interferon in the blood of people with cancer who are starting immunotherapy, and people with certain autoimmune diseases (such as lupus, Sjögren's syndrome, scleroderma, or inflammatory myopathy). The goal is to compare interferon patterns and better understand immune responses.
Pamplona, NavarreAges 18 years+
Hear when a new Adverse Event trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for adverse event?
- Yes. Clin2 currently lists 191 recruiting adverse event studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a adverse event trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a adverse event trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.